IMBA is lead participant in a new, cell-based medicine initiative for Europe

LifeTime, which counts Jürgen Knoblich, scientific director at IMBA, as a leading member, has developed a strategy to integrate breakthrough-technologies that will further develop personalised treatment for cancer, cardiovascular and metabolic disorders, chronic inflammation, infectious diseases, and neurological disorders.

Read the full story here